Influence of bradykinin and ACE inhibitors on selected biochemical markers of oxidative stress in rats with induced ischemia-reperfusion syndrome

• Autorzy: Krauss H , Sosnowski P. , Grzymislawski M. , Kozlik J. , Jablecka A. , Balcer N. , Bednarek A.
• Języki publikacji: EN

Abstrakty

EN

Cessation of blood flow in tissues leads to depletion of energetic resources of cells, disturbances in the activity of enzymes of the oxidative chain and electrolyte disorders, as well as to the production of reactive oxygen species. A great deal of attention has been paid to those problems since they are responsible for most of the complications in the ischemia-reperfusion (I/R) syndrome. Understanding the antioxidative mechanisms involved in I/R syndrome provides us with the potential to correct at least some of the resulting disturbances. One of the potentially beneficial factors is insulin. This observation directed our attention to the insulin-like factors, kinins (especially bradykinin), the activation of which was detected in I/R syndrome. The effect of bradykinin is modified by concurrent administration of the specific antagonists of bradykinin receptors, B1 and B2. The aim of the current study was to assess the role of bradykinin. In the study, the employed agents included the angiotensin converting enzyme inhibitor, which prevents the degradation of endogenous kinins, and blockers of bradykinin receptors, which abolish the influence of kinins. We observed that after 4 hours of ischemia followed by reperfusion, levels of free radicals in tissues as well as levels of peroxides in plasma increased significantly. Administration of bradykinin, captopril or enalapril resulted in the decline of these free radical levels. The application of B2 receptor antagonist decreased the beneficial influence of bradykinin, whereas B1 receptor antagonist revealed no significant effect. Activities of antioxidative enzymes (superoxide dismutase, catalase, and glutathione peroxidase) were measured. After 4 hours of ischemia and consecutive steps of reperfusion, a statistically significant increase in their activities was observed when bradykinin or ACE inhibitors were administered. Application of B2 receptor blockers reduced the effect of bradykinin, whereas the effect of B1 receptor antagonists was minute.

Słowa kluczowe

EN

rat; oxidative stress; ischaemia-reperfusion syndrome; biochemical marker; bradykinin; ACE inhibitor zob.angiotensin converting enzyme inhibitor; angiotensin converting enzyme inhibitor; reactive oxygen species

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2007
• Tom: 63
• Numer: 09
• Opis fizyczny: p.1052-1056,fig.,ref.

Twórcy

autor

Krauss H

• University of Medical Sciences, Swiecickiego 6, 60-781 Poznan, Poland

autor

Sosnowski P.

autor

Grzymislawski M.

autor

Kozlik J.

autor

Jablecka A.

autor

Balcer N.

autor

Bednarek A.

Bibliografia

• 1.Auch-Schwelk W., Duske E., Claus M., Graf K., Grafe M., Fleck E.: Endothelium mediated vasodilation during ACE inhibition. Eur. Heart. J. 1995, 16 (suppl C), 59-65.
• 2.Clapperton M., McMurray J., Fisher A., Dargie H. J.: The effect of angiotensin-converting enzyme inhibitors on human neutrophil chemotaxis in vitro. Br. J. Clin. Pharmacol. 1994, 38, 53-66.
• 3.Cohen M. V.: Free radicals in ischemic an reperfusion myocardial injury: Is this the time for clinical trials. Ann. Intern. Med. 1989, 111, 918-931.
• 4.Dietze G.: Modulation of the action of insulin in relation to the energy state in skeletal muscle tissue possible involvement of kinins and prostaglandins. Mol. Cell. Endocrinol. 1982, 25, 127-149.
• 5.Egan T. M., Minta J. O., Scrimgeour K. G., Cooper J. D.: Captopril a potential free radical scavenger. Inhibition of PMN NADPH oxidase. Clin. Invest. Med. 1988, 11, 351-356.
• 6.Feng J., Li H., Rosenkranz E. R.: Bradykinin protects the rabbit heart after cardioplegic ischemia via NO-dependent pathways. Ann. Thorac. Surg. 2000, 70, 2119.
• 7.Fenoy F. J., Scicli G., Carretero O., Roman R. J.: Effect of an angiotensin II and a kinin receptor antagonist on the renal hemodynamic response to captopril. Hypertension 1991, 17, 1038-1044.
• 8.Galik A., Weissgarten J., Evans S., Cohen N., Zaidenstein R., Modai D., Cotariu D.: Changes in red blood cell glutathione and glutathione-dependent enzymes on long-term treatment with captopril and enalapril. Clin. Chim. Acta 1995, 240, 89-94.
• 9.Hartl W. H., Jauch K. W., Herndon D. N., Cohnert T. U., Wolfe R. R., Schildberg F. W.: Effect of low-dose bradykinin on glucose metabolism and nitrogen balance in surgical patients. Lancet 1990, 335, 69-71.
• 10.Kobara M., Tatsumi T., Kambayashi D., Mano A.: Effects of ACE inhibition on myocardial apoptosis in an ischemia-reperfusion rat heart model. J. Cardiovasc. Pharmacol. 2003, 41, 880-885.
• 11.Koźlik J., Krauss H., Paluszak J., Sosnowski P., Mikrut K.: Effect of insulin on free radical level in tissues of rats with streptozotocin diabetes mellitus (in Polish). Molekularne i fizjologiczne aspekty regulacji ustrojowej. Mat. IV Międzynarod. Symp.Tatranske Matiary 1995, p. 188-190.
• 12.Li Y., Sato T.: Dual signaling via protein kinase C and phosphatidylinositol 3’-kinase/Akt contributes to bradykinin B2 receptor-induced cardioprotection in guinea pigs hearts. J. Mol. Cell. Cardiol. 2001, 33, 2047.
• 13.Little C., O’Brien P. J.: An intracellular GSH-peroxidase with a lipid peroxidase substrate. Biochem. Biophys. Res. Comm. 1968, 31, 145-150.
• 14.Lowry O. H., Rosenbrough N. J., Fara A. L., Randall R. L.: Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265-275.
• 15.Lumenta D., Plesnila N., Klasner B., Baethmann A., Pruneau D., Schmid- -Elsaesser R., Zausinger S.: Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia. Brain. Res. 2006, 1069, 227-234.
• 16.Marceau F., Hess J. F., Bachvarov D.: The B1 receptors for kinins. Pharmacol. Rev. 1998, 50, 357.
• 17.Margolius H. S.: Tissue kallikreins and kinins: regulation and roles in hipertensive and diabetic disease. Ann. Rev. Pharamacol. Toxical 1989, 29, 343-364.
• 18.Mikrut K., Paluszak J., KoŸlik J., Sosnowski P., Krauss K., Grzeœkowiak E.: The effect of bradykinin on the oxidative state of rats with acute hyperglycaemia. Diabetes Res. Clin. Pract. 2001, 51, 79-85.
• 19.Mira M. L., Silva M. M., Queiros M. J., Manso C. F.: Angiotensin converting enzyme inhibitors as oxygen free radicals scavengers. Free Radic. Res. Commun. 1993, 19, 173-178.
• 20.Misra H. P., Fridovich J.: The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J. Biol. Chem. 1972, 247, 3170-3175.
• 21.Munoz C. M., Leeb-Lundberg L. M. F.: Receptor mediated internalization of bradykinin DPT1 MF-2 smooth muscle cells process internalized bradykinin via multiple degadative pathways. J. Biol. Chem. 1992, 267, 303-309.
• 22.Needleman P. S., Key S. L., Denny S. E., Isaksson P. L., Marshall G. R.: Mechanisms and modification of bradykinin-induced coronary vasodilation. Proc. Natl. Acad. Sci. 1975, 72, 2060-2063.
• 23.Ohkawa H., Ohishi N., Yagi K.: Assay for lipid peroxides in animal tissues tiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351-358.
• 24.Saxena A. K., Srivastava P., Baquer N. Z.: Effect of vanadate on glycolytic enzymes and malic enzyme in insulin-dependent and independent tissues of diabetic rat. Eur. J. Pharmacol. 1992, 216, 123-126.
• 25.Schindler R., Dinarello C. A., Koch K. M.: Angotensin-converting enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin-1 by human peripheral blood mononuclear cells. Cytokine 1995, 7, 526-533.
• 26.Souza D. G., Lomez E. S. L., Pinho V., Pesquero J. B., Teixeira M. M.: Role of bradykinin B2 and B1 receptors in the local, remote and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J. Immunology 2004, 172, 2542-2548.
• 27.Tepel M., Heidenreich S., Zhu Z., Walter M., Nofer J.: Captopril inhibits the agonist induced increase of cytosolic free Ca2+ in glomelural mesangial cells. Kidney Int. 1994, 46, 696-702.
• 28.van Gilst W. H., de Graeff P. A., Wesseling H., de Langen C. D. J.: Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: A comparison of captopril, enalapril and HOE 498. J. Cardiovasc. Pharmacol. 1986, 8, 722-728.
• 29.Zieden B., Wuttge D. M., Karlberg B. E., Olsson A. G.: Effect of in vitro addition of captopril on copper induced low-density lipoprotein oxidation. Br. J. Clin. Pharmacol. 1995, 39, 201-203.